The minimum concentration (Cmin) levels of rituximab following cycle 3 (cycle 4 pre-dose) in DLBCL patients in Study GO29044 had a GMR of 1.47 (90% CI 1.26–1.72) when compared with Study BO22334 (R-CHOP) in the absence of pola (Table 4). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.